Purpose Given the toxic nature and narrow therapeutic index of traditional
chemotherapeutics, better methods of dose and therapy selection are critical …

Determining the correct dosage for the majority of traditional chemotherapeutic agents
presents a challenge because most drugs have a narrow therapeutic index, which results in …

Simple Summary Accelerated clinical development of anticancer drugs is crucial to ensure
patients' access to the most safe and effective treatments. At the same time, the development …

The complex nature of the pharmacologic aspects of cancer therapeutics has become more
apparent in the past several years with the arrival of a cascade of target-based agents and …

The development of clinical practice recommendations or guidelines for the clinical use of
pharmacogenomics data is an essential issue for improving drug therapy, particularly for …

The current trend to personalize anticancer therapies mostly relies on selecting the best
drug or combination of drugs to achieve optimal efficacy in patients. In addition to the …

Cancer pharmacogenomics have contributed a number of important discoveries to current
cancer treatment, changing the paradigm of treatment decisions. Both somatic and germline …

Background: Drugs for targeted therapies are primarily Small Molecules Inhibitors (SMIs),
monoclonal antibodies (mAbs), interfering RNA molecules and microRNA. The use of these …

The purpose of this article is to acknowledge the challenges in optimizing the dosing of
oncology drugs and to propose potential approaches to address these challenges in order …

Cancer pharmacogenomics is an evolving landscape and has the potential to significantly
impact cancer care and precision medicine. Harnessing and understanding the genetic …